Literature DB >> 9275021

Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse.

K Vanderkerken1, H De Raeve, E Goes, S Van Meirvenne, J Radl, I Van Riet, K Thielemans, B Van Camp.   

Abstract

The aim of this study was to evaluate the tissue infiltration and phenotypic adhesion profile of 5T2 multiple myeloma (MM) and 5T33 MM cells and to correlate it with that observed in human disease. For each line, 30 mice were intravenously inoculated with myeloma cells and at a clear-cut demonstrable serum paraprotein concentration; mice were sacrificed and a number of organs removed. The haematoxylin-eosin stainings on paraffin sections were complemented with immunohistochemistry using monoclonal antibodies developed against the specific MM idiotype. When analysed over time, 5T2 MM cells could be observed in bone marrow samples from week 9 after transfer of the cells. For the 5T33 MM, a simultaneous infiltration was observed in bone marrow, spleen and liver 2 weeks after inoculation. Osteolytic lesions consistently developed in the 5T2 MM, but this was not consistent for 5T33 MM. PCNA staining showed a higher proliferative index for the 5T33 MM cells. The expression of adhesion molecules was analysed by immunohistochemistry on cytosmears: both 5T2 MM and 5T33 MM cells were LFA-1, CD44, VLA-4 and VLA-5 positive. We conclude that both lines have a phenotypic adhesion profile analogous to that of human MM cells. As the 5T2 MM cells are less aggressive than the 5T33 MM cells, their organ distribution is more restricted to the bone marrow and osteolytic lesions are consistently present, the former cell line induces myeloma development similar to the human disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9275021      PMCID: PMC2227997          DOI: 10.1038/bjc.1997.409

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Histologic, biochemical, and clinical parameters for monitoring multiple myeloma.

Authors:  R Bartl; B Frisch; H Diem; M Mündel; D Nagel; R Lamerz; A Fateh-Moghadam
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

2.  Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues.

Authors:  P Galand; C Degraef
Journal:  Cell Tissue Kinet       Date:  1989-09

3.  Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules.

Authors:  M M Kawano; N Huang; H Tanaka; H Ishikawa; A Sakai; O Tanabe; M Nobuyoshi; A Kuramoto
Journal:  Br J Haematol       Date:  1991-12       Impact factor: 6.998

4.  Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma.

Authors:  E J Ahsmann; H M Lokhorst; A W Dekker; A C Bloem
Journal:  Blood       Date:  1992-04-15       Impact factor: 22.113

5.  Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; J Sany; P Baldet; C Alexandre
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

6.  Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice.

Authors:  J Radl; E D De Glopper; H R Schuit; C Zurcher
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

7.  Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.

Authors:  J Brissinck; C Demanet; M Moser; O Leo; K Thielemans
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

8.  Analysis of proliferating hepatocytes using a monoclonal antibody against proliferating cell nuclear antigen/cyclin in embedded tissues from various liver diseases fixed in formaldehyde.

Authors:  N Kawakita; S Seki; H Sakaguchi; A Yanai; T Kuroki; Y Mizoguchi; K Kobayashi; T Monna
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

9.  Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.

Authors:  J Radl; J W Croese; C Zurcher; M H van den Enden-Vieveen; R J Brondijk; M Kazil; J J Haaijman; P H Reitsma; O L Bijvoet
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

10.  VLA-4-fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion.

Authors:  E Roldán; A García-Pardo; J A Brieva
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  41 in total

1.  Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.

Authors:  Caroline Rousseau; Ludovic Ferrer; Stéphane Supiot; Manuel Bardiès; François Davodeau; Alain Faivre-Chauvet; Pierre Baumgartner; John Wijdenes; Marie Lacombe; Jacques Barbet; Thierry Guillaume; Philippe Moreau; Jean Luc Harousseau; Françoise Kraeber-Bodéré; Michel Cherel
Journal:  Tumour Biol       Date:  2012-03-03

2.  Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells.

Authors:  Karin Vanderkerken; Isabelle Vande Broek; Décio L Eizirik; Els Van Valckenborgh; Kewal Asosingh; Ivan Van Riet; Ben Van Camp
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

3.  Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

Authors:  Abdel Kareem Azab; Jinsong Hu; Phong Quang; Feda Azab; Costas Pitsillides; Rana Awwad; Brian Thompson; Patricia Maiso; Jessica D Sun; Charles P Hart; Aldo M Roccaro; Antonio Sacco; Hai T Ngo; Charles P Lin; Andrew L Kung; Ruben D Carrasco; Karin Vanderkerken; Irene M Ghobrial
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

4.  Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.

Authors:  Apollina Goel; Angela Dispenzieri; Susan M Geyer; Suzanne Greiner; Kah-Whye Peng; Stephen J Russell
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

5.  Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

Authors:  Michelle M McDonald; Michaela R Reagan; Scott E Youlten; Sindhu T Mohanty; Anja Seckinger; Rachael L Terry; Jessica A Pettitt; Marija K Simic; Tegan L Cheng; Alyson Morse; Lawrence M T Le; David Abi-Hanna; Ina Kramer; Carolyne Falank; Heather Fairfield; Irene M Ghobrial; Paul A Baldock; David G Little; Michaela Kneissel; Karin Vanderkerken; J H Duncan Bassett; Graham R Williams; Babatunde O Oyajobi; Dirk Hose; Tri G Phan; Peter I Croucher
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

6.  Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Authors:  Els Van Valckenborgh; Peter I Croucher; Hendrik De Raeve; Chris Carron; Evy De Leenheer; Sylvia Blacher; Laetitia Devy; Agnès Noël; Elke De Bruyne; Kewal Asosingh; Ivan Van Riet; Ben Van Camp; Karin Vanderkerken
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

7.  Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.

Authors:  Deepti Soodgupta; Haiying Zhou; Wissam Beaino; Lan Lu; Michael Rettig; Mark Snee; James Skeath; John F DiPersio; Walter J Akers; Richard Laforest; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

8.  Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Authors:  Kewal Asosingh; Eline Menu; Els Van Valckenborgh; Isabelle Vande Broek; Ivan Van Riet; Ben Van Camp; Karin Vanderkerken
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

9.  Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model.

Authors:  Hendrik R De Raeve; Kewal Asosingh; Eddie Wisse; Ben Van Camp; Eric Van Marck; Karin Vanderkerken
Journal:  Virchows Arch       Date:  2004-06-30       Impact factor: 4.064

10.  Cell Trafficking in Multiple Myeloma.

Authors:  Giada Bianchi; Shaji Kumar; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2012-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.